pharma · Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation · Myelodysplastic Syndrome · PMVP
PMV Pharmaceuticals
MV Pharmaceuticals is a pharma organization headquartered in PRINCETON, NJ, USA. It trades on NYSE under ticker PMVP. Primary therapeutic focus areas include Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y
PRINCETON, NJ, USA HQ
4 Employees
Public company Type
PMVP · NYSE Ticker
Company details
- Status
- Public
- HQ
- PRINCETON, NJ, USA
- Employees
- 4
- Programs
- 6
- Drugs
- 5
- Patents
- 11
Azacitidine
Phase 1 · small molecule · Myelodysplastic Syndrome
Azacitidine for Myelodysplastic Syndrome is a Phase 1 program (small_molecule) at PMV Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code 2024-0371
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- PMV Pharmaceuticals
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Myelodysplastic Syndrome
- Status
- active
- Trials
- 1